Unique ID issued by UMIN | UMIN000030108 |
---|---|
Receipt number | R000034376 |
Scientific Title | Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease |
Date of disclosure of the study information | 2017/11/24 |
Last modified on | 2019/05/27 20:23:22 |
Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease
PVTED study
Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease
PVTED study
Japan |
Portal vein thrombosis
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Others
NO
Evaluate the usefulness of edexaban tosilate hydrate for portal vein thrombosis associated with chronic liver disease.
Efficacy
Reduction rate of portal vein thrombus 14 days after edoxaban administration
Safety of edoxaban administration against portal vein thrombosis
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Edoxaban 30 to 60 mg / day for 14 days
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Clinically (histologically or imagewise) diagnosed as chronic liver disease.
2) Patients who have been confirmed to have thrombus in the portal vein, superior mesenteric vein, or / and splenic vein on the image.
3) The latest inspection value within 14 days before registration (same day as two weeks before the registration day is acceptable) satisfies all of the following.
Hemoglobin 9.0 g / dl or more (male), 8.0 g / dl or more (female)
Platelet count 50,000 / mm 3 or more
Creatinine clearance 30 ml / min or more
4) Child-Pugh classification A or B.
5) Weight 40 kg or more.
6) About participation in the examination Informed consent is obtained from the patient himself.
1. Child-Pugh classification C.
2. Endoscopic examination confirms the presence of lesions at risk of gastrointestinal bleeding (esophageal gastric varices, gastric / duodenal ulcers, gastric antral vascular dilation, etc.), and does not perform prophylactic treatment.
3. Have active malignancy.
4. Patients taking anticoagulant or / and antiplatelet drugs.
5. Patients with a history of clear bleeding symptoms such as cerebral haemorrhage.
6. Patients who weigh less than 40 kg at registration.
7. A woman who is pregnant or has a possibility of pregnancy, within 28 days after childbirth or breast-feeding. A man who wishes to become a partner's pregnant.
8. Mental illness or psychiatric symptoms are merged and it is judged that participation in the examination is difficult.
9. It has severe hypersensitivity to the ingredients of Edoxaban.
10. Because of drug allergy, neither CT nor MRI using a contrast agent can be performed.
11. Others, the doctor in charge determines that participation in this examination is inappropriate.
20
1st name | |
Middle name | |
Last name | Shuichi Kaneko |
Kanazawa University Hospital
Gastroenterology / Hepatobiliary and pancreatic surgery
13-1,Takara-machi,Kanazawa city
076-265-2000
skaneko@m-kanazawa.jp
1st name | |
Middle name | |
Last name | Hajime Takatori |
Kanazawa University Hospital
Gastroenterology
13-1,Takara-machi,Kanazawa city
076-265-2000
takatori@m-kanazawa.jp
Kanazawa University Hospital
Kanazawa University Hospital
Other
NO
2017 | Year | 11 | Month | 24 | Day |
Unpublished
Terminated
2017 | Year | 10 | Month | 26 | Day |
2017 | Year | 12 | Month | 12 | Day |
2017 | Year | 12 | Month | 18 | Day |
2019 | Year | 05 | Month | 31 | Day |
2017 | Year | 11 | Month | 24 | Day |
2019 | Year | 05 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034376
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |